Associate Director, Biostatistics
Pubblicato il 10-09-2026 - Iqvia in Cagliari
Job Description
IQVIA Biotech has an exciting position within its EU Biostats team. As the Biotech and Emerging Biopharma arm of IQVIA, we continue to grow and win new business. Historically IQVIA Biotech focused on Oncology, Dermatology and Medical Device studies but with the addition of CNS, Immunology and Cardiovascular we have a need for a strong Lead Statistician.
We’re looking for enthusiastic and independent professionals with great communication skills who are willing to work from home with an international team. This is the perfect opportunity to join an established department and develop leadership skills.
IQVIA Biotech specialises in working with smaller biotech and emerging biopharma clients and as such we have a vibrant, fast-paced work environment. You’ll be working with a lot of the new innovative and upcoming research groups across a variety of therapy areas.
The ideal candidate will possess extensive oncology drug development experience across a broad range of oncology indications,
with demonstrated expertise in applying advanced statistical methodologies throughout the clinical development lifecycle.
They should have the technical expertise to provide senior-level statistical review and oversight of Statistical Analysis Plans (SAPs), ADaM specifications and datasets, Tables, Listings, and Figures (TLFs), and other key study deliverables, ensuring scientific rigor, quality, and consistency across programs.
The candidate will be an effective people leader with a proven ability to mentor, develop, and support biostatistical staff across global regions, including Europe and JPAC.
Strong customer engagement and relationship management skills are essential, including the ability to serve as a trusted statistical advisor to emerging biopharma customers who may have limited experience with clinical development, regulatory requirements, and statistical considerations.
The successful candidate will also have experience supporting regulatory submissions and i